Benralizumab reduces eosinophils but does not improve eosinophilic gastritis
Treatment with benralizumab induced histological remission, defined as an absence of tissue eosinophilia, among patients with eosinophilic gastritis, according to a study published in The Lancet Gastroenterology & Hepatology.But the persistence of signs, symptoms and biomarkers of the disease during treatment suggested a pathogenic mechanism independent of eosinophil levels in many patients,
Source: healio.com
